Axolotl Biologix Launches New DualGraft™ For Faster Healing
Regenerative Medicine Patch Advances Wound Repair
Phoenix, AZ (January 23, 2018) – To help physicians facilitate wound healing, Axolotl Biologix, a biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl DualGraft™, a bi-layered human amnion membrane patch that serves as a barrier to protect wounds while advancing skin repair and reconstruction.
Axolotl’s DualGraft promotes healing of damaged tissue by using amniotic components to create a biological scaffolding which stimulates cells to repair themselves. This 3-dimensional extracellular matrix scaffold encourages cell migration and proliferation needed for healing.
DualGraft™ also helps to establish an environment in the wound to lower the growth of bacteria and reduce the rate of infection in chronic wounds, such as diabetic ulcers. Since it is conveniently packaged as a terminally irradiated, dehydrated allograft, it can be stored at room temperature and applied in a clinical setting.
“We our proud to offer physicians our new Axolotl DualGraft to help promote healing in wounds and improve patient outcomes in a number of clinical applications,” said Dr. Robert Kellar, Chief Science Officer of Axolotl Biologix. “DualGraft is the newest addition to our line of products in the space of regenerative medicine.”
“Research has demonstrated amniotic membrane products, like DualGraft, have clinical benefits that will help physicians and wound care specialists,” said Dr. Robert Diller, Senior Director of Research. “This is only the beginning as we research and develop new technologies to help people age without losing their ability to stay active.”
Amnion membrane used in DualGraft™ are derived from the amniotic lining of the placenta following a scheduled cesarean section. The donated amniotic membrane is recovered and processed aseptically in accordance with all FDA guidelines and quality assurance standards in a controlled environment.
About Axolotl Biologix:
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com
10 to 1 Public Relations
10 to 1 Public Relations